CRP and type 2 diabetes mellitus: The authors found that the reduction in LV mass caused by empagliflozin was independent of baseline NLR [24], which is consistent with our finding showed that the reduction in LV mass caused by dapagliflozin was not significantly different in patients with T2D and stage B HF, regardless of baseline level of CRP or other inflammatory cytokines.